We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+42.63%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$906M
AUM Growth
-$90.1M
Cap. Flow
-$241M
Cap. Flow %
-26.64%
Top 10 Hldgs %
57.8%
Holding
54
New
5
Increased
4
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$17.3M
2
VRNA
Verona Pharma
VRNA
+$12.6M
3
TERN
Terns Pharmaceuticals
TERN
+$12M
4
PCVX icon
Vaxcyte
PCVX
+$10.3M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.87M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$183M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$62.4M
3
HRMY icon
Harmony Biosciences
HRMY
+$33.8M
4
VTYX
Ventyx Biosciences
VTYX
+$12.5M
5
CLDX icon
Celldex Therapeutics
CLDX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.5%
2 Materials 2.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTCR
51
DELISTED
Metacrine, Inc. Common Stock
MTCR
$71K 0.01%
146,426
– –
DSGN icon
52
Design Therapeutics
DSGN
$862M
– –
-476,589
Closed -$6.67M
ZYME icon
53
Zymeworks
ZYME
$1.7B
– –
-286,064
Closed -$1.52M
SRRA
54
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-3,329,509
Closed -$183M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Vivo Capital held 54 positions worth $906M, down 9% from $996M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Vivo Capital withdrew a net $241M in Q3 2022, closing 3 positions and reducing 7 holdings. Its most notable exit was Sierra Oncology, Inc. Common Stock, an estimated $183M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Materials.

Against the trend, Vivo Capital opened a new position in Allakos worth $25.2M.

  • Vivo Capital's largest Q3 2022 buy was Allakos: 4,120,134 shares worth $25.2M.
  • Vivo Capital added most to Verona Pharma in Q3 2022, an estimated $12.6M increase.
  • Vivo Capital's biggest Q3 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $62.4M.
  • Vivo Capital fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $183M.
  • Vivo Capital's ten largest holdings make up 58% of its $906M portfolio in Q3 2022.
  • Vivo Capital opened 5 new positions and closed 3 in Q3 2022.
  • Vivo Capital's portfolio value fell 9% quarter-over-quarter to $906M.

Based on Vivo Capital's 13F filing for Q3 2022, filed 14 Nov 2022.